GlassScriptPhysician profile
Jocelyn Laporta
NPI 1285493296
$472.61
in general payments reported to CMS, 2019-2025
11 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $172 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117.40 | 2024-2025 | |
| Novo Nordisk INC | $73.04 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Ardelyx, INC. | $43.80 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.35 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $41.73 | 2024-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $40.71 | 2024 | Trintellix |
| Verona Pharma, INC. | $33.00 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $31.32 | 2024 | Airsupra |
| Lilly USA, LLC | $19.92 | 2025 | Jardiance |
| Exact Sciences Corporation | $15.26 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $14.08 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Laporta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.